# Siraj M. Ali

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/siraj-m-ali/

## Facts

| Field | Value |
| --- | --- |
| Citations | 49,868 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 95 |
| i10-index | 306 |
| Last Known Institution | UPMC Hillman Cancer Center |
| OpenAlex ID | https://openalex.org/A5088809839 |
| ORCID iD | https://orcid.org/0000-0001-7477-4023 |
| Works | 802 |

## Researcher papers

Showing 12 of 13.

- [Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden](https://scholariq.org/papers/analysis-of-100-000-human-cancer-genomes-reveals-the-landscape-of-tumor/)
- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors](https://scholariq.org/papers/activation-of-met-via-diverse-exon-14-splicing-alterations-occurs-in-multiple/)
- [Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade](https://scholariq.org/papers/targeted-next-generation-sequencing-identifies-markers-of-response-to-pd-1/)
- [Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer](https://scholariq.org/papers/immune-activation-and-response-to-pembrolizumab-in-pole-mutant-endometrial/)
- [Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations](https://scholariq.org/papers/characterization-of-298-patients-with-lung-cancer-harboring-met-exon-14-skipping/)
- [Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement](https://scholariq.org/papers/open-label-multicenter-phase-ii-study-of-ceritinib-in-patients-with-non-small/)
- [AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations](https://scholariq.org/papers/aeneas-a-randomized-phase-iii-trial-of-aumolertinib-versus-gefitinib-as-first/)
- [Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer](https://scholariq.org/papers/immune-activation-and-benefit-from-avelumab-in-ebv-positive-gastric-cancer/)
- [Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients](https://scholariq.org/papers/comprehensive-characterization-of-ras-mutations-in-colon-and-rectal-cancers-in/)
- [Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing](https://scholariq.org/papers/genomic-alterations-in-head-and-neck-squamous-cell-carcinoma-determined-by/)
- [Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma](https://scholariq.org/papers/clinical-genomic-profiling-in-the-management-of-patients-with-soft-tissue-and/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [UPMC Hillman Cancer Center](https://scholariq.org/institutions/upmc-hillman-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.